Lilly to sell hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals
Eli Lilly and Company (Lilly) has agreed to sell its severe hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals in a deal potentially worth up to $1.07 ... Read More
Fintech platform Airwallex raises $100m funding at $5.5bn valuation
Airwallex has raised $100m in a Series E extension funding round that valued the Australian fintech company at $5.5bn. With the latest funding, the Melbourne-founded ... Read More